Upside – $ALEC +58% (global AL050 license brings $100M upfront, up to $1.17B in milestones and extends the cash runway into 2029) – $PCVX +55% (VAX-31 OPUS-1 pivotal Phase 3 trial met all prespecified primary endpoints with a safety profile comparable to existing vaccines) – $PTC +36% (agrees to a $205-a-share all-cash takeover valuing its …
Read in context ›RXO, Inc. Stock (RXO)
Track RXO, Inc. stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
RXO
RXO, Inc.
industrials
At close
$29.08
▲ +0.15 (+0.52%)
Oct 9, 4:00 PM ET
After-hours
$29.05
▼ -0.03 (-0.10%)
Oct 9, 7:30 PM ET
Market Cap
$4.77B
P/E Ratio
—
1Y Return
+64.67%
EPS (TTM)
-$0.62
Read the latest TheStreet Pro articles mentioning RXO, Inc., including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
1 articleDaily Diary Mentions
1 mentionUpside, Downside Movers in the Morning